The National Institutes of Health (
Advancing Innovation at the National Institutes of Health
More than 30 years ago, there was no effective treatment for CF, and little was known about the disease. In 1989, Francis S. Collins, MD, PhD, who is now the director of the NIH, co-identified the CF gene. In the more than three decades since, incredible progress has been made in the understanding of CF and development of therapies for people living with CF. These scientific advances, along with a comprehensive approach to care, are changing the face of the disease.
The NIH provides the foundational support for
Today, the CF Foundation works closely with the NIH to support basic science and
Advancing Therapies Through the Food and Drug Administration
A well-resourced FDA helps ensure new drugs are safe and effective and are swiftly reviewed to get them into the hands of people with CF as soon as possible. The CF Foundation’s work with policymakers helps ensure that the FDA proactively seeks meaningful input from patients, providers, and researchers when reviewing applications for rare disease treatments. Through our policy work, we aim to help the FDA accelerate drug review timelines while maintaining the highest standards of approval.